BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 36925073)

  • 1. Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study.
    Peled N; Roisman LC; Levison E; Dudnik J; Chernomordikov E; Heching N; Dudnik E; Keren-Rosenberg S; Nechushtan H; Salhab A; Hershkovitz D; Tsuriel S; Hannes V; Rotem O; Lazarev I; Lichtenberg R; Granot IS; Krayim B; Shalata W; Levin D; Krutman Y; Allen AM; Blumenfeld P; Lavrenkov K; Kian W
    Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):105-114. PubMed ID: 36925073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
    Nassar AH; Kim SY; Aredo JV; Feng J; Shepherd F; Xu C; Kaldas D; Gray JE; Dilling TJ; Neal JW; Wakelee HA; Liu Y; Lin SH; Abuali T; Amini A; Nie Y; Patil T; Lobachov A; Bar J; Fitzgerald B; Fujiwara Y; Marron TU; Thummalapalli R; Yu H; Owen DH; Sharp J; Farid S; Rocha P; Arriola E; D'Aiello A; Cheng H; Whitaker R; Parikh K; Ashara Y; Chen L; Sankar K; Harris JP; Nagasaka M; Ayanambakkam A; Velazquez AI; Ragavan M; Lin JJ; Piotrowska Z; Wilgucki M; Reuss J; Luders H; Grohe C; Baena Espinar J; Feiner E; Punekar SR; Gupta S; Leal T; Kwiatkowski DJ; Mak RH; Adib E; Naqash AR; Goldberg SB
    J Thorac Oncol; 2024 Jun; 19(6):928-940. PubMed ID: 38278303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.
    Lu S; Casarini I; Kato T; Cobo M; Özgüroğlu M; Hodge R; van der Gronde T; Saggese M; Ramalingam SS
    Clin Lung Cancer; 2021 Jul; 22(4):371-375. PubMed ID: 33558193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.
    Chang AEB; Piper-Vallillo AJ; Mak RH; Lanuti M; Muzikansky A; Rotow J; Jänne PA; Mino-Kenudson M; Swanson S; Wright CD; Kozono D; Marcoux P; Piotrowska Z; Sequist LV; Willers H
    Oncologist; 2024 May; ():. PubMed ID: 38761385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer.
    Rusch VW; Nicholas A; Patterson GA; Waqar SN; Toloza EM; Haura EB; Raz DJ; Reckamp KL; Merritt RE; Owen DH; Finley DJ; McNamee CJ; Blasberg JD; Garon EB; Mitchell JD; Doebele RC; Baciewicz F; Nagasaka M; Pass HI; Schulze K; Johnson A; Bunn PA; Johnson BE; Kris MG; Kwiatkowski DJ; Wistuba II; Chaft JE; Carbone DP; Lee JM
    J Thorac Cardiovasc Surg; 2023 Mar; 165(3):828-839.e5. PubMed ID: 36369159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
    Tsuji K; Mizugaki H; Yokoo K; Kobayashi M; Kawashima Y; Kimura N; Yokouchi H; Kikuchi H; Sumi T; Kawai Y; Kobashi K; Morita R; Ito K; Kitamura Y; Minemura H; Nakamura K; Aso M; Honjo O; Tanaka H; Takashina T; Tsurumi K; Sugisaka J; Tsukita Y; Konno S; Oizumi S
    Cancer Sci; 2024 Apr; 115(4):1273-1282. PubMed ID: 38287788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study.
    Lee J; Ahn HK; Kim SW; Han JY; Lee SS; Park HS; Lee HW; Kim JH; Cho E; Huggenberger R; Cho BC
    Cancer Med; 2024 Apr; 13(7):e7174. PubMed ID: 38622869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations.
    Nygård L; Ahlborn LB; Persson GF; Chandrananda D; Langer JW; Fischer BM; Langer SW; Gabrielaite M; Kjær A; Rosenfeld N; Mouliere F; Østrup O; Vogelius IR; Bentzen SM
    PLoS One; 2020; 15(4):e0231884. PubMed ID: 32343749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib after Chemoradiotherapy in Stage III
    Lu S; Kato T; Dong X; Ahn MJ; Quang LV; Soparattanapaisarn N; Inoue T; Wang CL; Huang M; Yang JC; Cobo M; Özgüroğlu M; Casarini I; Khiem DV; Sriuranpong V; Cronemberger E; Takahashi T; Runglodvatana Y; Chen M; Huang X; Grainger E; Ghiorghiu D; van der Gronde T; Ramalingam SS;
    N Engl J Med; 2024 Jun; ():. PubMed ID: 38828946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease.
    Sathiyapalan A; Baloush Z; Ellis PM
    Curr Oncol; 2023 Oct; 30(11):9514-9529. PubMed ID: 37999109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non-Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial.
    Shin J; Park S; Kim KH; Shin EC; Jung HA; Cho JH; Sun JM; Lee SH; Choi YS; Ahn JS; Kim J; Park K; Shim YM; Kim HK; Noh JM; Ahn YC; Pyo H; Ahn MJ
    Cancer Res Treat; 2024 Apr; ():. PubMed ID: 38697848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using Novel Statistical Techniques to Accurately Determine the Predictive Dose Range in a Study of Overall Survival after Definitive Radiotherapy for Stage III Non-Small Cell Lung Cancer in Association with Heart Dose.
    Niska JR; Hu J; Li J; Herman MG; Thorpe CS; Schild SE; Fatyga M
    J Cancer Ther; 2021 Sep; 12(9):505-529. PubMed ID: 34804634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017.
    Damhuis RAM; Dickhoff C; Bahce I; Senan S
    Lung Cancer; 2024 Apr; 190():107532. PubMed ID: 38461767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective cohort study of unresectable stage III non-small-cell lung cancer in Canada.
    Seung SJ; Hurry M; Walton RN; Evans WK
    Curr Oncol; 2020 Aug; 27(4):e354-e360. PubMed ID: 32905267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations.
    Hong DS; Cappuzzo F; Chul Cho B; Dowlati A; Hussein M; Kim DW; Percent I; Christensen JG; Morin J; Potvin D; Faltaos D; Tassell V; Der-Torossian H; Chao R
    Lung Cancer; 2024 Apr; 190():107512. PubMed ID: 38417277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy with Helical TomoTherapy Versus Conventional Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicenter, Randomized Phase 3 Trial.
    Zhang Q; Fan S; Xu X; Du S; Zhu G; Jiang C; Xia SA; Li Q; Wang Q; Qian D; Zhang M; Xiao H; Chen G; Zeng Z; He J
    Int J Radiat Oncol Biol Phys; 2024 Apr; ():. PubMed ID: 38631536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pamiparib as consolidation treatment after concurrent chemoradiotherapy of limited-stage small cell lung cancer: a single-arm, open-label phase 2 trial.
    Mao J; Ni J; Chu L; Chu X; Xu D; Yang X; Zhu Z
    Radiat Oncol; 2024 Apr; 19(1):47. PubMed ID: 38610031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors.
    Friedes C; Iocolano M; Lee SH; Li B; Duan L; Levin WP; Cengel KA; Sun LL; Aggarwal C; Marmarelis ME; Doucette A; Cohen RB; Xiao Y; Langer CJ; Bradley J; Feigenberg SJ; Yegya-Raman N
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1435-1444. PubMed ID: 37866762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Phase II Study of Radiotherapy Dose Escalation in Grade 4 Glioma Using
    Madan R; Kumar N; Dracham CB; Kumar R; Trivedi G; Tripathi M; Sahoo SK; Singla N; Ahuja CK; Chatterjee D; Yadav A; Goyal S; Khosla D
    Clin Oncol (R Coll Radiol); 2024 Apr; ():. PubMed ID: 38821722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study.
    Varlotto JM; Sun Z; Ky B; Upshaw J; Katz SI; Fitzgerald TJ; Wakelee H; Diehn M; Mankoff DA; Lovely C; Belani C; Oettel K; Masters G; Ramalingam S; Pennell NA
    Oncologist; 2021 Jun; 26(6):523-532. PubMed ID: 33594771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.